A leader from clinical-stage pharma firm NuCana shares promising results for its ProTides therapies and hopes the drugs can elevate outcomes for patients.
Nanoscale silica bottles, a five-hundredth of the diameter of a hair, could be used to deliver cancer drugs to specific disease sites in the body, avoiding debilitating side effects.
A natural substance found in stinging nettles and ants repeatedly attacks cancer within cells, say scientists developing low-dose alternatives to current chemotherapy drugs.
Seaweed extracts can reduce tumour growth and improve the effectiveness of chemotherapy says Marinova, which is developing the compounds for pharmaceutical applications.
Cure Pharmaceutical has entered into a strategic collaboration to test and develop potential cancer therapeutics utilising a blend of the cannabis plant-derived terpenes.
Researchers from the Oncology Department of Tianjin Medical University Cancer Hospital in China recently published a study in Advanced Functional Materials announcing the creation of a new nano-carrier for pancreatic cancer treatments.
Divested sterile manufacturer Ben Venue has continued to cause trouble for Boehringer Ingelheim with a second recall this year of an injectable drug made at the now defunct site.
Parallel deals to invest in Isofol Medical and manufacture the alternative chemotherapy agent Modufolin on its behalf are evidence of Recipharm’s ambitious growth strategy, the CDMO says.
Roche will build an antibody-drug conjugate production facility to support production of its approved drug Kadcyla and others in its development pipeline.
AmerisourceBergen has bought informatics firm IntrinsiQ for $35m (€25m) continuing the spending spree it began earlier this week with the acquisition of market access consultancy Premier Source.
in-PharmaTechnologist presents a roundup of the latest drug delivery research, including bone marrow targeting nanoparticles and an imaging-treatment combo.
Researchers at the Georgia Institute of Technology have pioneered a multi-compartment gel capsule that could be used to simultaneously deliver drugs of different types.
Scientists from the University of Syracuse’s chemistry department have created a new drug delivery system which they claim will improve the efficacy of cancer-killing drugs.
in-PharmaTechnologist.com’s latest round up of developments in drug delivery includes Critical Pharmaceuticals’ sustained release hGH, Phase III results for AP Pharma and nanodiamonds.
Cephalon has licensed the hydrophobic drug delivery system (HDDS)
and a reformulated version of paclitaxel, called AI-850, from
Acusphere in a $10m deal.
US-based Delcath Systems has achieved positive results in treating
diffuse liver cancer using its percutaneous hepatic perfusion (PHP)
delivery system.
Japanese drugmaker Eisai has agreed to buy US biopharma firm MGI
Pharma for $3.9bn (€2.7bn) in a bid to expand its US presence and
strengthen its oncology pipeline.
Two manufacturers launched their docetaxel products at CPhI last
week, each trying to stake their claim in the market in
anticipation of patent expiries on Sanofi-Aventis' Taxotere
(docetaxel) towards the end of the year.
SAFC has announced its plans to build a new high potency
conjugation suite at its Missouri manufacturing plant in order to
target pharma clients developing novel anti-cancer drug conjugates.
Bioxel Pharma is the latest company to submit a Drug Master File
(DMF) to the US Food and Drug Administration (FDA) for docetaxel in
the lead up to the patent expiring on Sanofi-Aventis' version of
the cytotoxic chemical at the...
GlaxoSmithKline (GSK) has stopped development of several drugs,
leaving some industry experts to wonder if the company's cap on
research spending is stifling drug development.
A Japanese firm announced this week that it has developed a
biodegradable polymer based drug delivery system that could
significantly improve the efficacy of chemotherapy drugs and reduce
drug development costs.
A new anti-cancer drug delivery system which allows more targeted
treatment and helps avoid the unsafe and unpleasant side effects of
chemotherapy is due to enter clinical trials in Europe and the US
for use with anti-cancer drug...
Forbes has highlighted the important role of nanotechnology in
driving forward the pharmaceutical industry with three of their top
five nanotech breakthroughs in 2006 having biological applications.
Onyx Pharmaceuticals have fallen out of the race to find a badly
needed new treatment for skin cancer after their lead drug tripped
up in its final stage clinical trial.
Canadian pharma manufacturer Bioxel has announced it has received
several orders for its paclitaxel product - a taxane-based drug
effective to treat cancer - from two European customers
representing a total of CAD$630,000 (€420,000).
Canadian pharma manufacturer Bioxel has announced the filing of a
second international patent application to secure the synthesis of
paclitaxel and decetaxel - two taxane-based drugs effective against
cancer.
Scientists are looking into the possibility of using bacteria to
make a new library of anti-cancer compounds that are usually too
difficult to create synthetically. The discovery could provide the
basis for developing useful new anti-cancer...
Researchers believe that a little-known antibiotic could well prove
effective against cancer, showing promise because it has not shown
toxic side effects, which continue to blight current anti-cancer
agents.
Drug researchers have turned to an unusual source to boost the
efficacy of a particular anticancer drug by investigating the
properties of a mushroom that has been used for centuries in
Eastern Asian medicine.
Genentech and Inotek have entered into a strategic alliance in
which they will concentrate on the discovery, development and
commercialisation of PARP inhibitors for cancer - a class of drug
that has demonstrated high efficacy in...
Bioxel, a company which manufactures and markets taxane active
pharmaceutical ingredients (APIs) used in chemotherapeutic drugs,
has turned to two contract manufacturing companies to scale up
production.
A new method being developed to deliver chemotherapy to cancer
patients without incurring side effects could also reduce patient
numbers who die from the effects of chemotherapy caused by the high
doses to tackle the cancer.
A unique DNA-based targeting technology has shown to halt tumour
progression with significantly smaller chemotherapy doses opening
the way to reduce the side effects as well as increase the efficacy
of anti cancer therapies.
CuraGen and TopoTarget have announced preliminary data suggesting
its small molecule candidate may have potential anti-tumour
activity against haematologic cancer.
Researchers in the US have uncovered a contributing factor in
interferon resistance of malignant melanoma cells. The finding
represents a step forward in understanding of this type of cancer
and the changes in gene and cellular signalling...
French drug delivery company Novagali Pharma has completed
early-stage clinical testing of an oral formulation of paclitaxel,
a widely used cancer drug usually delivered by intravenous
infusion.
Researchers, for the first time, have revealed the forms taken by
structures of tubulin during the construction of microtubules. The
discovery is of use to drug researchers and developers as tubulin
is a target for anticancer drugs,...
Novagali Pharma, a biopharmaceutical company developing innovative
drug delivery systems, has started a Phase I clinical trial in
patients with advanced cancer for its oral formulation of the
cancer drug paclitaxel.
Scientists have reported that a molecule previously thought to play
a purely structural and inert role in cells may play a key role in
bringing about multidrug resistance in cancer.
